Literature DB >> 17279007

Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia.

Gulten Secmeer1, Ilker Devrim, Ates Kara, Mehmet Ceyhan, Bulent Cengiz, Tezer Kutluk, Munevver Buyukpamukcu, Sevgi Yetgin, Murat Tuncer, Ali Kerem Uludag, Hasan Tezer, Inci Yildirim.   

Abstract

In clinical practice, when neutropenic-fever patients present with no microbiologically and clinically defined infection, the risk of underestimating an occult infection is of major concern, the clinicians have to make a decision on when to modify antibiotic therapy. Hence, a reliable, specific, and sensitive marker, which is regulated independently from the leukocyte count and the underlying disease, is needed for the early diagnosis of infections in cases of neutropenic fever. We have evaluated the diagnostic and follow-up value of procalcitonin (PCT) compared with C-reactive protein (CRP) and erythrocyte sedimentation rate in documenting the infection in neutropenic-fever patients undergoing intensive chemotherapy, as evidenced by the durational change in these parameters in the presence of defined infection. Forty-nine patients, who had 60 febrile episodes, and who were hospitalized in the Hacettepe University Ihsan Doğramaci Children's Hospital between January 1, 2004 and January 1, 2005 were included in this prospective study. All patients had been diagnosed with neutropenic fever after intensive chemotherapy. In our study, PCT and CRP levels were significantly higher in neutropenic-fever patients (group I and group II separately) than in control patients (P<0.001) throughout the study period; but erythrocyte sedimentation rate levels did not show any significant difference (P>0.05). In sequential analyses of patients without documented infections, the median of PCT concentrations shows a tendency to fall after the 8th hour of onset of fever, whereas in patients with documented infections PCT concentrations fell after the 48th hour. In conclusion, our study suggests that PCT, when measured periodically, is a more useful diagnostic inflammation parameter in pediatric neutropenic-fever patients than CRP, both in estimating the severity of the infection and, the duration and origin of the fever. Hence, PCT might be helpful when deciding on initial therapy modification.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17279007     DOI: 10.1097/MPH.0b013e3180320b5b

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  11 in total

1.  Diagnostic accuracy of lipopolysaccharide-binding protein for predicting bacteremia/clinical sepsis in children with febrile neutropenia: comparison with interleukin-6, procalcitonin, and C-reactive protein.

Authors:  Lidija Kitanovski; Janez Jazbec; Sergej Hojker; Metka Derganc
Journal:  Support Care Cancer       Date:  2013-09-21       Impact factor: 3.603

Review 2.  Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis.

Authors:  Chun-Wei Wu; Jiunn-Yih Wu; Chun-Kuei Chen; Shiau-Ling Huang; Shou-Chien Hsu; Meng-Tse Gabriel Lee; Shy-Shin Chang; Chien-Chang Lee
Journal:  Support Care Cancer       Date:  2015-02-21       Impact factor: 3.603

3.  The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia.

Authors:  Karin G E Miedema; Eveline S J M de Bont; Rob F M Oude Elferink; Michel J van Vliet; Claudi S M Oude Nijhuis; Willem A Kamps; Wim J E Tissing
Journal:  Support Care Cancer       Date:  2010-08-28       Impact factor: 3.603

Review 4.  Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer.

Authors:  Robert S Phillips; Ros Wade; Thomas Lehrnbecher; Lesley A Stewart; Alex J Sutton
Journal:  BMC Med       Date:  2012-01-18       Impact factor: 8.775

5.  Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults.

Authors:  Karin S R Massaro; Silvia F Costa; Claudio Leone; Dalton A F Chamone
Journal:  BMC Infect Dis       Date:  2007-11-22       Impact factor: 3.090

6.  Presepsin (scd14) as a marker of serious bacterial infections in chemotherapy induced severe neutropenia.

Authors:  Elham Olad; Iraj Sedighi; Azim Mehrvar; Maryam Tashvighi; Vahid Fallahazad; Amirabbas Hedayatiasl; Hossein Esfahani
Journal:  Iran J Pediatr       Date:  2014-11-28       Impact factor: 0.364

7.  Early Changes of Mannose-Binding Lectin, H-Ficolin, and Procalcitonin in Patients with Febrile Neutropenia: A Prospective Observational Study.

Authors:  Sibel Işlak Mutcalı; Neşe Saltoğlu; İlker İnanç Balkan; Reşat Özaras; Mücahit Yemişen; Fehmi Tabak; Ali Mert; Recep Öztürk; Şeniz Öngören; Zafer Başlar; Yıldız Aydın; Burhan Ferhanoğlu; Teoman Soysal
Journal:  Turk J Haematol       Date:  2015-08-06       Impact factor: 1.831

8.  Procalcitonin and C-reactive protein in differantiating to contamination from bacteremia.

Authors:  Lutfiye Oksuz; Ayper Somer; Nuran Salman; Osman Erk; Nezahat Gurler
Journal:  Braz J Microbiol       Date:  2015-03-04       Impact factor: 2.476

Review 9.  Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  W J Heinz; D Buchheidt; M Christopeit; M von Lilienfeld-Toal; O A Cornely; H Einsele; M Karthaus; H Link; R Mahlberg; S Neumann; H Ostermann; O Penack; M Ruhnke; M Sandherr; X Schiel; J J Vehreschild; F Weissinger; G Maschmeyer
Journal:  Ann Hematol       Date:  2017-08-30       Impact factor: 3.673

10.  Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia.

Authors:  Hilde T van der Galiën; Erik A H Loeffen; Karin G E Miedema; Wim J E Tissing
Journal:  Support Care Cancer       Date:  2018-05-19       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.